Comparative Pharmacology
Head-to-head clinical analysis: INGENOL MEBUTATE versus PICATO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INGENOL MEBUTATE versus PICATO.
INGENOL MEBUTATE vs PICATO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ingenol mebutate is a macrocyclic diterpene ester that induces rapid, mitochondria-dependent cell death (necrosis) in dysplastic keratinocytes upon topical application. It also activates protein kinase C (PKC) isoforms, specifically PKCδ, leading to mitochondrial dysfunction and release of pro-apoptotic factors. Additionally, it stimulates a local immune response via neutrophil-mediated oxidative burst and antibody-dependent cellular cytotoxicity.
Ingenol mebutate is a diterpene ester that induces rapid necrosis of dysplastic epidermal cells following topical application. It exerts its effects through activation of protein kinase C (PKC) isoforms, leading to mitochondrial disruption, loss of membrane integrity, and cell death. Additionally, it induces a localized inflammatory response with neutrophil infiltration.
0.05% gel applied topically to the lesion once daily for 2 consecutive days per treatment course; repeat after 3 weeks if needed.
Apply topically once daily to each lesion for 2 consecutive days per treatment course. Maximum of 1 tube per dose. Treatment area should not exceed 25 cm².
None Documented
None Documented
Terminal half-life approximately 18–24 hours; supports twice-daily application for actinic keratosis treatment.
Terminal half-life is approximately 21 hours (range 13–48 hours) in patients with actinic keratosis; no significant accumulation observed with once-daily dosing.
Primarily hepatobiliary excretion into feces; minimal renal elimination (<1% unchanged).
Primarily biliary/fecal (approximately 80% of absorbed dose), with renal excretion accounting for <5% of the dose as metabolites.
Category C
Category C
Topical Antineoplastic
Topical Antineoplastic